Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEY-MELT: pembrolizumab after partial breast irradiation in early triple-negative breast cancer
KCT0010781Phase 2Not yet recruiting
- Sponsor
- National Research Foundation
- Start
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in triple-negative breast cancer (TNBC), sponsored by National Research Foundation. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on KCT0010781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010781.